Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Average Price Target of $6.17 According to Analysts

Treace Medical Concepts logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Treace Medical Concepts has an average analyst rating of Hold from five firms, with a consensus 12-month price target of $6.17.
  • Analyst views are mixed: UBS and Stifel upgraded the stock to Buy, while Truist maintained Hold and Weiss downgraded its rating to Sell.
  • The company reported quarterly EPS of -$0.19, beating estimates of -$0.25, and revenue of $48.25 million, above expectations. CEO John Treace also bought 11,000 shares at an average price of $4.34.
  • MarketBeat previews top five stocks to own in December.

Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Get Free Report) have earned an average rating of "Hold" from the five research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.17.

Several research analysts have issued reports on TMCI shares. Truist Financial increased their price target on Treace Medical Concepts from $4.00 to $5.00 and gave the stock a "hold" rating in a report on Monday, August 10th. Weiss Ratings downgraded Treace Medical Concepts from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday. UBS Group upgraded Treace Medical Concepts from a "neutral" rating to a "buy" rating in a research note on Monday, November 9th. Finally, Stifel Nicolaus raised shares of Treace Medical Concepts from a "hold" rating to a "buy" rating and increased their price target for the company from $4.50 to $6.50 in a research note on Monday, November 9th.

Check Out Our Latest Stock Analysis on TMCI

Insider Activity at Treace Medical Concepts

In related news, CEO John Treace bought 11,000 shares of Treace Medical Concepts stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average price of $4.34 per share, with a total value of $47,740.00. Following the purchase, the chief executive officer owned 7,404,383 shares in the company, valued at $32,135,022.22. This represents a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 23.42% of the stock is owned by corporate insiders.

Institutional Trading of Treace Medical Concepts

A number of hedge funds and other institutional investors have recently modified their holdings of TMCI. Goldman Sachs Group Inc. increased its stake in shares of Treace Medical Concepts by 21.4% in the third quarter. Goldman Sachs Group Inc. now owns 597,572 shares of the company's stock worth $2,653,000 after buying an additional 105,456 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Treace Medical Concepts during the third quarter valued at approximately $235,000. Empowered Funds LLC acquired a new position in shares of Treace Medical Concepts during the third quarter worth approximately $328,000. Gagnon Securities LLC lifted its position in shares of Treace Medical Concepts by 12.8% in the 3rd quarter. Gagnon Securities LLC now owns 3,415,918 shares of the company's stock worth $15,167,000 after acquiring an additional 386,375 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Treace Medical Concepts during the 2nd quarter worth approximately $282,000. 84.08% of the stock is owned by hedge funds and other institutional investors.

Treace Medical Concepts Price Performance

Shares of TMCI opened at $4.53 on Thursday. The company has a market cap of $296.99 million, a P/E ratio of -5.27 and a beta of 1.59. The company has a debt-to-equity ratio of 0.91, a current ratio of 2.58 and a quick ratio of 1.66. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $5.44. The stock has a fifty day moving average price of $4.42 and a 200 day moving average price of $3.38.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its earnings results on Friday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.06. The business had revenue of $48.25 million for the quarter, compared to analyst estimates of $47.80 million. Treace Medical Concepts had a negative net margin of 27.44% and a negative return on equity of 72.99%. On average, research analysts forecast that Treace Medical Concepts will post -0.80 earnings per share for the current year.

Treace Medical Concepts Company Profile

(Get Free Report)

Treace Medical Concepts, Inc. develops and markets medical devices for foot and ankle surgery, with a focus on treatments for bunions and related deformities. Its products are designed for use by surgeons in correcting and stabilizing bones and joints in the foot. The company's offerings include the Lapiplasty 3D Bunion Correction System, which uses specialized instruments and fixation implants to support correction of bunion deformities in three dimensions. Treace also sells systems and implants for other foot and ankle procedures, including treatments for deformities involving the midfoot and big toe.

Featured Stories

Analyst Recommendations for Treace Medical Concepts (NASDAQ:TMCI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Treace Medical Concepts Right Now?

Before you consider Treace Medical Concepts, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.

While Treace Medical Concepts currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines